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Abstract 
 
Purpose   Bisphosphonates are established as a supportive therapy for a number 
of malignancies which metastasise to bone. Previous reports also suggest potent anti-
tumour and antiangiogenic properties. We investigated the in vitro activity of two 
aminobisphosphonates, pamidronate (PAM) and zoledronic acid (ZOL) on the growth 
and survival of three renal cell carcinoma cell lines (Caki-2, 769-P and D69581).  
Experimental design   Cell lines were exposed to bisphosphonates in vitro and 
evaluated by MTS (3-(4,5-dimethylahiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay and  cell cycle analysis. Mechanisms of apoptotic 
cell death was investigated by Apo-Direct assay, western blot and by KinetworksTM 
Analyses 
Results ZOL was consistently more potent than PAM in inducing apoptotic 
cell death.  ZOL was capable of overcoming resistance to PAM in one cell line. 
Addition of isoprenoids only partially reduced the effects of ZOL and PAM. Although 
ultimately less potent, the inhibitory effects of PAM appear earlier than ZOL. The 
proapototic effect of ZOL was through non-mitochondrial pathways and was 
associated with activation of caspase 6, caspase 3 and PARP (poly ADP-
ribosyltransferase polymerase) cleavage. Furthermore, we observed a marked 
reduction in, and intracellular distribution of,  MSH2, a protein involved in DNA 
mismatch repair, as well as evidence of a greater cellular response to ZOL as 
increased expression of superoxide dismutase. 
Conclusion  These findings add further support to the clinical use of 
aminobisphosphonates, particularly ZOL, for RCC patients with metastatic disease to 
bone. 
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Introduction 
 
There are no satisfactory treatment options for renal cell carcinoma (RCC)  in the 
advanced stage; even palliation of symptoms is problematic due to the inherent 
chemo- and radio-resistance of RCC. The incidence of renal cell carcinoma has been 
increasing steadily over the last twenty years and has been estimated that bone 
metastases will develop in approximately 30% of patients (1).  Bony involvement 
may lead to considerable morbidity including bone pain, pathological fractures, 
hypercalcemia and spinal cord compression (2).  It has been reported that 
approximately 81% of patients with RCC with bone metastases require radiotherapy. 
Of these patients 42% experience long bone fracture and 29% require orthopaedic 
surgery or develop hypercalcemia at some point during the course of their disease (1). 
Bone metastases associated with RCC rarely respond to systemic treatment.   
 
Bisphosphonates (BP) are analogues of endogenous pyrophosphate and inhibit bone 
reabsorption at the level of the osteoclast. They have become increasingly useful in 
patients with metastatic bone disease. BP have been used extensively in the treatment 
of postmenopausal osteoporosis (3), corticosteroid-induced bone loss (4) , Pagets 
disease (5), patients with hypercalcemia of malignancy, and in the prevention of 
skeletal complications associated with bony metastases in patients with multiple 
myeloma and breast cancer (6-10). Although not associated with improved overall 
survival in any malignancy, intravenous zoledronate (ZOL) has also been shown to 
reduce the percentage of patients experiencing skeletal related events in a range of 
other malignancies including renal cell carcinoma, lung cancer and prostate cancer 
(11) (12) (13)  and breast cancer and multiple myeloma. 
 
Several recent studies have suggested that these compounds have not only strong anti-
osteoclastic activity, but also a direct antitumour effect. Aminobisphosphonates 
inhibit squalene synthase (14), disrupt prenylation of small GTP proteins (15),  inhibit 
tyrosine phosphatase activity (16) and reduce invasion and adhesion by disruption of  
matrix metalloproteinase secretion (17).  BP may also be capable of interfering with 
growth and survival of metastatic cancer cells in bone (18) (19) (20) by altering the 
release of growth factors into in the bone microenvironment. They may also exert an 
antiangiogenic effect  (21). In addition, aminobisphosphonates have been found to  
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dramatically increase apoptosis in macrophage, myeloma-derived, prostate and 
pancreatic cancer cell lines (22, 23) (24) 
 
Third generation nitrogen-containing BP such as ZOL inhibit farnesyldiphosphate 
synthase, an enzyme involved in the mevalonate pathway preventing the post-
translational events of prenylation of small GTP-binding proteins such as p21 ras.  
Rab, Rho, Rac abd cdc42 (15) , required for functions such as signal transduction and 
cell adhesion.  There are reports of synergy with chemotherapy and biological 
therapies (25) (26) 
 
A number of studies have reported on the effects of BP directly on growth and 
survival of cancer cell lines derived from solid malignancies. ZOL induces a 
reduction in cell viability, increased apoptotic death and downregulation of bcl-2, 
p21ras delocalization from the cell membrane and proteolytic cleavage of PARP, 
indicating direct antitumour effects in breast cancer cell lines (27). In prostate cancer, 
ZOL inhibited cell proliferation by induction of cell death and /or cytostasis in vitro 
(28). In pancreatic cancer lines, commonly associated with p21ras dysregulation,  the 
effects of BP was to interfere with growth and survival pathways downstream of p21 
ras. ZOL treatment resulted in  apoptotic death and caspase 9 (but not caspase 3) 
activation (24).  
 
In this study we have evaluated the effect of two aminobisphosphonates, pamidronate 
(PAM) and zoledronate (ZOL) on the growth and survival of three RCC cell lines in 
vitro. Although the frequency of KRAS mutation is low in RCC, this evaluation was 
proposed based on the observation of activated HRAS oncogenes in human RCC with 
single point mutations within codon 12 and 61, and the reported clinical effects of 
zoledronic acid in RCC (29) (30) (31). Two of the three cell lines were sensitive to 
both PAM and ZOL; both agents were capable of significant growth inhibition and 
inducing cell death. The third cell line showed a differential sensitivity to BP with 
resistance to even prolonged exposure to PAM and failure of caspase 3 activation. 
This cell line was studied in more detail using an apoptosis protein screening assay to 
gain more insight into the mechanism of apoptotic death in the cells susceptible to 
ZOL. 
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Materials and Methods 
 
Cell Lines 
Human renal cell lines 769-P, Caki-2 were obtained from ATCC. The cell lines were 
derived from primary clear cell adenocarcinomas (769-P and Caki-2) or from lymph 
node metastasis of a clear cell adenocarcinoma (D69581). 769P and MCF-7 were 
maintained in RPMI-1640, 10% FCS, 2.05 mM L-Glutamine, 100 U/ml penicillin and 
0.1 mg/ml streptomycin. Caki-2 was maintained in McCoy's 5A, 10% FCS, 1.5 mM 
L-Glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin.  Human renal cell line 
D69581 was a gift from Onyvax Ltd and was maintained in DMEM, 10% FCS, 4 mM 
L-Glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin. All cell lines were 
maintained at 37°C in a humidified 5% CO2 environment and were routinely screened 
for mycoplasma contamination. 
 
Bisphosphonate Dosage Studies 
Tumour cells were allowed to grow to 80% confluency, were washed once in PBS 
and removed from plates with trypsin/EDTA. Trypsin/EDTA activity was stopped by 
adding fresh medium and FCS. Cells were seeded at a density of 1x104 in 96-well 
plates and allowed to adhere overnight.  Media was then replaced with 100 µl/well 
serum-free media containing various concentrations (0,10 and 100 M) of ZOL 
(Novartis) and PAM (Faulding Pharmaceuticals plc). For comparison, the effects of  
first generation bisphosphonate clodronate (Sigma UK)was used. Clodronate lacks 
primary and tertiary amino groups which PAM and ZOL contain respectively. At time 
points 30 minutes, 1 hour, 3 hours, 24 hours, 48hours and 72 hours after drug 
addition, 20 µl/well CellTiter 96® Aqueous One Solution reagent (Promega, UK) was 
added and after a further 1-4 h incubation plates were read at 450 nm.  In some 
experiments the drugs were replaced by normal media after 6 and 24 h, and the MTS 
assay performed 72 h after initial drug addition. The optical density (OD 450 nm) of 
media plus CellTiter 96® Aqueous One Solution reagent was subtracted from all 
readings and results calculated as % viable cells. 
 
 
 
 6
Apo-Direct Assay 
Tumour cells were seeded into flasks and allowed to adhere overnight.  Media was 
then replaced with serum free media containing either no drug, ZOL or PAM.  72 h 
after drug addition floating and adherent cells were harvested, combined and fixed 
with 10% paraformaldehyde and stored at -20°C in 70% ethanol, according to the 
manufacturer,s instructions. DNA breaks in the cells were then labelled with FITC-
dUTP following manufacturer’s instructions and samples were analysed on a 
FACScan machine.  Data was analysed using WinMDi (Scripps). 
 
Cell Lysis and SDS-PAGE 
Cells were treated with no drug, 100 µM ZOL or 100 µM PAM for 72 h.  Adherent 
and non-adherent cells were harvested into cold PBS, washed and resuspended in 
lysis buffer (50 mM Trizma, 150 mM NaCl, 0.1% v/v Triton X-100, 0.8 µg/ml 
aprotinin, 3 µg/ml PMSF) and incubated on ice for 2 h.  The cell lysates were 
microfuged at full speed for 10 min at 4°C to remove cell debris, and the supernatants 
aliquoted and stored at -80°C.  Protein concentration was estimated using Bio-Rad 
Protein Assay  with bovine serum albumin standards following the microassay 
procedure in the manufacturer’s instructions. 
Approximately 25 µg of protein/well was run by SDS-PAGE on a 12% resolving gel 
and transferred to Hybond-C Extra nitrocellulose membrane. 
 
Protein Detection 
β-actin was detected using the Actin (Ab-1) Kit (Oncogene™ Research Products).  
Bax was detected using a rabbit polyclonal Anti-Bax antibody (Santa Cruz 
Biotechnology, Inc) at a dilution of 1:200 and the anti-rabbit IgG-HRP secondary Ab 
from the ECL™ Western Blotting System (Amersham, UK). Bcl-2 was detected 
using a mouse monoclonal Anti-Bcl-2 antibody (Santa Cruz Biotechnology, Inc) at a 
dilution of 1:100 and the anti-mouse IgG-HRP secondary Ab from the ECL™ 
Western Blotting System.  Inducible heat shock protein 70 (iHsp70) was detected 
using mouse Anti-Hsp70 monoclonal antibody (Stressgen #SPA-810) at a dilution of 
1:1000 and the anti-mouse IgG-HRP secondary Ab from the ECL™ Western Blotting 
System.  The ECL™ Western Blotting System was used to visualise both proteins. 
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KinetworksTM Analyses 
For the preparation of cytosolic fractions for KinetworksTM analyses, cells were 
homogenized using a Dounce homogenizer in lysis buffer without NaCl and Nonidet 
P-40. The lysis buffer  consisted of the following: 20 mM MOPS pH 7.0, 2 mM 
EGTA, 5 mM EDTA, 30 mM sodium fluoride, 40 mM -glycerophosphate pH 7.2, 10 
mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonylfluoride, 3 mM benzamidine, 5 M pepstatin A, 10 M 
leupeptin. After ultracentrifugation at 100,000 rpm for 30 min at 4 °C, the supernatant 
was collected as a cytosolic fraction. The pellet fraction was then rehomogenized in 
lysis buffer with NaCl and 0.5% Nonidet P-40. After ultracentrifugation, the 
detergent-solubilized supernatant was saved as a particulate fraction. KinetworksTM 
analyses were performed on 300-600 µg of protein/sample. The immunoblotting 
analyses involved probing with mixes of in-house validated primary antibodies from 
commercial sources and the application of each mix into a separate lane of a 20-lane 
multiblotter (Immunetics). Detailed protocols for the KinetworksTM analyses can be 
found at the Kinexus Bioinformatics website (www.kinexus.ca). 
 
Caspase-3 Assay 
Caki-2 cells were treated with no drug, 100 µM ZOL or 100 µM PAM for 72 h.  
Adherent and non-adherent cells were harvested into cold PBS, washed and 
resuspended in lysis buffer (10 mM HEPES pH 7.3, 2 mM EDTA, 0.1% NP40, 5 mM 
DTT, 1 mM PMSF, 10 µg/ml pepstatin A, 10 µg/ml leupeptin, 10 µg/ml aprotinin) 
and incubated on ice for 15 min.  The cell lysates were microfuged at full speed for 10 
min at 4°C to remove cell debris, and the supernatants aliquoted and stored at -80°C.  
Protein concentration was estimated using Bio-Rad Protein as described above. 
Approximately 18 µg of protein in a 20 µl volume was added to 178 µl reaction 
buffer (100 mM HEPES pH 7.3, 20% v/v glycerol, 0.5 mM EDTA, 5 mM DTT)in 
triplicate in a black 96-well plate.  2 µl of caspase-3 substrate Ac-DEVD-AMC 5 mM 
in 4% DMSO (BioSource) was added.  Free AMC was measured using a Packard 
Fusion fluorometer with a 380 nm excitation and a 460 nm emission filter, over a time 
course.  Background fluorescence (reaction buffer/substrate alone) was subtracted and 
fluorescence units plotted against time.  Results shown represent AMC release over a 
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1 h period of the straight-line portion of the graph and are calculated as a percentage 
of “no drug”. 
 
Assessment of the effects of farnesyl transferase inhibitor and isoprenoids 
Farnesol mixed isomers (FOH, 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol) and 
geranylgeraniol (GGOH, 3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-ol) (both 
from Sigma, Poole, UK), as cell permeable analogues of FPP and GGPP, were added 
to cells 3 hours before treating with zoledronic acid, to bypass any suppression of 
prenylation caused by inhibition of the mevalonate pathway. Both were reconstituted 
in 100% ethanol. Manumycin A (Sigma, UK) wasused to directly inhibit protein 
prenylation, and compare the results with zoledronic acid. Manumycin A is a 
naturally occurring farnesyltransferase inhibitor (FTI) All reagents were diluted in 
culture medium before adding to cell cultures.  
 
Detection of MSH2 protein  
Cells were seeded at a density of 1x105 on 12mm poly-L-lysine coated glass 
coverslips (BD Biosciences) and allowed to adhere overnight. After a brief rinse in 
PBS, the coverslips were immersed in ice-cold methanol and incubated at -20°C for 
10 min. The coverslips were air dried, rinsed with PBS and covered with blocking 
buffer (1% BSA, 1% human AB serum in PBS) for 30 min at 37°C. Blocking buffer 
was removed by aspiration and the coverslips were incubated with diluted anti-MSH2 
and relevant isotype control (BD Biosciences) for 1 hour at room temperature in the 
dark. The coverslips were washed three times in PBS (5 min) and incubated with 
diluted FITC-conjugated secondary antibody for 1 h at room temperature in the dark. 
The coverslips were washed three times in PBS (5 min) and images were collected on 
a Zeiss Axiovert 135 fluorescence microscope equipped with a Hamamatsu high 
resolution digital camera.  
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Results 
The effect of ZOL and PAM on the proliferation of renal carcinoma cell lines. 
The effect of ZOL and PAM on 769-P, Caki-2 and D69581 cells was investigated 
using the MTS assay.  The cell lines were exposed to between 0 and 100 mol of 
ZOL and 0 and 200 mol PAM,  and assessments made at a time points between 30 
minutes and 72 hours as recent reports with pancreatic cell lines indicated that very 
short exposures to bisphosphonate may affect their proliferation. There was 
differential sensitivity of cell lines to each of the compounds. We compared the 
effects clodronate on the same cell lines. All three lines eventually succumbed to the 
drug but at markedly high doses (>2000 mM), once again Caki-2 appeared to be least 
susceptible Figure 1. Caki 2 appeared to be generally resistant to both ZOL and PAM 
at 48 hours, but after 72 hours was only susceptible to ZOL at the highest dose. 
Increasing dose and time of exposure to PAM (over 200 mol and beyond 72 hours) 
did not result in any additional antiproliferative effects on this cell line (data not 
shown). D69581 appeared to be the most sensitive cell line to exposure to either 
bisphosphonate with loss of cell viability observed even after 30 minutes exposure. 
Both ZOL and PAM had activity on the 769-P cell line, with more pronounced cell 
kill with ZOL after 72 hour exposure. ZOL had a more pronounced antiproliferative 
effect at lower concentrations. In 769P and D69581 cells, we noted that although the 
onset of the effects of PAM appeared earlier than ZOL,  ZOL appeared to be more 
effective overall and exerted its maximal effect after more prolonged drug exposure. 
The maximal response to PAM appeared to be 48 hours and 1 hour respectively in 
these two lines, but by 72 hours there was evidence of significant cell proliferation to 
the lower doses of PAM. Figure 2. 
 
The effects of isoprenoid lipid analogues on bisphosphonate treatment 
Several studies have suggested that amino-containing bisphosphonates cause 
apoptosis by preventing post-translational modification of GTP-binding proteins with 
isoprenoid lipids. The possible role of protein prenylation was examined in our cell 
lines. Farnesyltransferase inhibition using manumycin resulted in cell death in all cell 
lines after 24 hours after exposure to 20M manumycin (data not shown). FOH and 
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GGOH can be used intracellularly for protein prenylation through a salvage pathway. 
The addition of FOH and GGOH only partially attenuated the effects of  ZOL 
(statistically significant for the addition of FOH) but not PAM at 24 hours. Figure 3.  
 
 
Assessment of mode of cell death 
After exposure to bisphosphonate at 100 mol (or no drug) for 72 hours, cells were 
harvested, fixed and stained for DNA fragmentation using FITC-dUTP.  
ZOL exposure resulted in high levels of apoptosis for the 769-P and D69581 lines 
(over 80%) with lower levels in the Caki-2 line ((39.67+/-9.10). Exposure to PAM 
resulted in apoptotic death in D69581 and  769-P cells but at lower levels that with 
ZOL treatment. Caki-2 cells were resistant to PAM at this and higher concentrations. 
Table 1. Morphological changes in each cell line after exposure to ZOL and PAM is 
shown in figure 4. 
 
Cell cycle analysis 
We investigated the effects of BP on the cell cycle using flow cytometry. Figure 5. 
Cell cycle analysis was performed on untreated control cells and after 72 hour 
exposure to ZOL and PAM. Each experiment was repeated at least five times. 
Untreated controls had few cells in the apoptotic peak, and had a distribution in the 
sub G1, G1, S and G2/M phases typical of proliferating cancer cells.  
For 769P there was a reduction in G1 (more pronounced with PAM), increase in S 
phase (more pronounced with PAM) and increase in G2/M (more pronounced with 
PAM). For D69581, an increase in sub G1 with ZOL was observed but again 
reduction in G1 and increase in S phase and G2/M much more pronounced with PAM 
than ZOL. Finally PAM had little effect on cell cycle on Caki-2 lines as expected, 
ZOL exposure resulted in marked increase in subG1 and a lesser increase in S phase 
and G2/M.  
 
Mechanism of apoptotic death 
We investigated the mechanism of apoptotic cell death in further detail in the Caki-2 
cell line in view of its differential susceptibility to ZOL and PAM. The analysis was 
undertaken using KinetworksTM KAPS gels on 300-600 µg of protein/sample 
extracted from the cytosol of treated and untreated cells. The immunoblotting 
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analyses involved probing with mixes of in-house validated primary antibodies from 
commercial sources and the application of each mix into a separate lane of a 20-lane 
multiblotter. This methodology has been published previously (32). However, a 
number of antibodies are not suitable for this analysis. For this reason, expression of 
bax and bcl-2 were performed by conventional western blot, and we used a separate 
assay to evaluate the effects of the two drugs on caspase 3 activation. 
 
The analyses showed that ZOL was a more potent inducer of apoptosis than PAM. 
There was no differential effect of bax and bcl-2 protein expression as shown by 
western blot suggesting that the mitochondrial-apoptosome mediated pathway was not 
activated (data not shown). Furthermore, caspase 3 activation was only observed in 
cell lines after exposure to ZOL. A representative assay is shown in figure 6. 
According to the Kinetiworks gel analysis, table 3, there was a 50% reduction of AIF 
(apoptosis-inducing factor) in both treated samples which may have resulted from its 
translocation into the nucleus.  Since CAS (Cellular Apoptosis Susceptibility protein) 
is thought to be involved in proliferation, further decrease of CAS in ZOL-treated 
cells compared to PAM-treated cells is consistent with the higher degree of apoptosis 
induced by ZOL treatment.  DFF45, the inhibitor of caspase-activated DNase, showed 
~70% decrease in the ZOL-treated samples versus ~30% in the PAM-treated sample, 
in keeping with the higher pro-apoptotic effect seen with ZOL. The reduction of 
MSH2 in the ZOL-treated sample may have been related to protein translocation into 
the nucleus for DNA repair caused by the treatment. We attempted to visualise the 
MSH-2 protein after ZOL and PAM exposure compared to untreated cells using 
immunofluorescence. We found that the appearance of cells after PAM exposure was 
similar to controls with concentration of fluorescence in the cell nucleus. After ZOL 
exposure however, the distribution of MSH2 protein changed markedly and adopted a 
peri-nuclear and cytoplasmic distribution, figure 7. Similarly, for PARP-1, its full-
length form p116 exhibited an 81% decrease in the ZOL-treated sample and more 
than 400% increase in the PAM-treated sample, indicating a higher degree of 
cleavage of PARP, which faciliates the disassembly of cells.  Most of caspases 
tracked in the screen showed more reduction in their pro-forms in the ZOL-treated 
sample than the PAM treated sample, which in agreement with the higher percentage 
of apoptotic cells in ZOL-treated sample. The increase of SOD(Cu/Zn), superoxide 
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dismutase [Cu-Zn], in the  ZOL-treated sample might have been cellular response to 
the stronger apoptosis-inducing capability of ZOL.  
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Discussion 
Bisphosphonates are potent inhibitors of bone resorption by inhibition of osteoclast 
function. The more potent nitrogen-containing bisphosphonates achieve this by 
inhibiting the mevalonate pathway by inhibiting the processing of G proteins which 
are essential for cell survival and function. Nitrogen-containing bisphosphonates 
disrupt intracellular processes and can cause apoptosis. ZOL, in particular, is a potent 
anti-resorptive nitrogen-containing bisphosphonate which is in regular clinical use for 
patients with osteoporosis, osteopaenia and cancer-related bone disease. To date, 
beneficial effects of bisphosphonates have been reported in renal cancer and other 
malignancies in terms of reduced pain, improved bone healing and reduced risk of 
pathological fracture. However,  there is little published preclinical work to support 
these clinical benefits of ZOL in renal cancer metastatic to bone. We have 
demonstrated its marked antiproliferative and apoptotic effects on three renal cell 
carcinoma cells lines, and its superior efficacy over PAM. Exposure to ZOL results in 
the induction of apoptosis through non-mitochondrial pathways. One clinical study 
has shown that treatment with ZOL reduced the risk of pathological fractures in 
patients with RCC. This study was a subgroup analysis so further work on RCC cell 
lines is needed. Bisphosphonates reduce skeletal complications of breast cancer, 
prostate cancer and multiple myeloma.  They may also affect tumour cells directly by 
inhibition of cell invasion or adhesion to bone matrix, or by growth inhibitory and/or 
apoptotic cell death. The apoptosis-inducing effects have been correlated to the 
antiresorptive properties of each bisphosphonate. The inhibitory effects of ZOL in 
vitro has been reported in breast cancer (27), prostate cancer (28) and multiple 
myeloma (33), pancreas (24). We found evidence of significant antiproliferative 
effects in a range 10-100 mol, consistent with previous studies. Responses to as little 
as 1 mol were also found early as 30 minutes in one cell line, and although ZOL was 
the more effective antiproliferative agent, it appeared to act much later than PAM. 
The effects of both bisphosphonates were abrogated to a small extent by the addition 
of isoprenoids suggesting that, similar to other models, these bisphosphonates were 
able to target the enzymes of the mevalonate pathway (34). The effect was more 
significant with the co-treatment with FOH than GGOH contrasting with other studies 
which have shown partial rescue with GGOH (35, 36). 
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Exposure of cell lines to ZOL and PAM resulted in different effects on the cell cycle 
in each line. The more profound pro-apoptotic effect of ZOL was reflected in 
increases in the subG1 peak in all three cell lines (most pronounced in D69581 and 
Caki-2). However, PAM was associated with a cytostatic effect as shown by the 
accumulation of cells in S phase and G2/M.  We  showed that in parallel with the 
antiproliferative effects mediated by the drug, ZOL also induces apoptotic cell death 
in all RCC cell lines. The apoptotic effect did not appear to involve the mitochondrial 
pathway as expression of bax and bcl-2 proteins were not perturbed. Furthermore, 
there was no clear evidence of  activation of FASL. We found a reduction in AIF after 
either treatment, and that most of the caspases tracked in the Kinexus gel showed a 
reduction of their pro forms after ZOL versus PAM treatment, consistent with the 
higher number of cells undergoing apoptosis.  Other findings were also consistent 
with a more powerful pro-apoptotic effect of ZOL. This included decreases in 
apoptosis inhibitors CAS and DFF45, and the dramatic reduction in MSH2, a protein 
involved in DNA mismatch repair. The increase in SOD was consistent with a higher 
cellular response to the stronger apoptosis-inducing capability of ZOL. There was no 
evidence of necrotic cell death and no induction of heat shock proteins (data not 
shown). Our observations for ZOL on RCC lines are consistent with other studies that 
ZOL-mediated apoptosis is associated with cytochrome c release and caspase 
activation. Caspase 3 is involved in the execution phase of apoptosis when proteolysis 
of intracellular substrates is a major event. Inhibition of caspase 3 prevents osteoclast 
apoptosis. In keeping with previous reports in breast cancer lines, we found clear 
evidence that only ZOL was capable of caspase 3 activation.in our cell line (27). 
Taken together, there is clear evidence of specific cellular effects of ZOL compared to 
PAM, which will be evaluated in a mouse xenograft model. 
 
Numerous studies suggest suggest direct anticancer effect of bisphosphonates even in 
the bone microenvironment. The positive effects of bisphosphonate on bone health in 
vivo is due to their ability to disrupt or alter paracrine interactions in the bone 
microevironment (37, 38). The evidence for this includes observations that 
bisphosphonates reduce IL-6 expression by osteoblasts (39) and  induce soluble 
inhibitors of osteoclast activity into conditioned media (40). Futhermore, osteoblasts 
express factors that promote the growth of prostate cancer cells but co-culture of 
tumour cells and osteoblasts suggest that ZOL is capable of directly inhibiting growth 
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of prostate cancer cells even when grown in the presence of an osteoblast cell line (41, 
42). However, bisphosphonates may also inhibit osteoclastic bone resorption through 
increased expression of factors such as osteoprotegerin by normal human osteoblasts 
(43).  
 
The concentrations required for to achieve effects were as low as 1 mol in our study. 
The issue of delivering adequate doses of bisphosphonate in clinical studies  has been 
discussed as a potential limitation as the typical serum levels of PAM vary between 
0.5-8 mol depending on the dosage and duration of infusion (44-48). Most in vitro 
studies like ours have used doses between 10 and 100 mol but antitumour effects 
have been observed in plasma cells and prostate cancer cell lines with doses as low as 
1 mol (35, 49). However, the local concentrations of bisphosphonates at the sites of 
active bone resorption may be much higher through their affinity for bone mineral 
(50). Strategies aimed at targeting higher concentrations of BP to bone using, for 
example, liposomal mediated delivery may be useful. 
 
Conclusion 
The important contribution of bisphosphonate therapy to the management of bone 
disease in breast cancer, prostate cancer and multiple myeloma is rapidly leading to its 
consideration for other malignancies. However, as we have shown in this study, the 
biological effects may vary depending on cell line and type of bisphosphonate used.   
We found that RCC cell lines are differentially susceptible to the effects of 
aminobisphophonates; ZOL is a more potent agent than PAM and ZOL may 
overcome resistance to PAM. ZOL targets the enzymes of the mevalonate pathway as 
expected, induces apoptosis through non-mitochondrial pathways but was also 
associated with high degrees of cellular stress as evidenced by induction of mismatch 
repair protein and superoxide dismutase. The safety and efficacy of these agents in the 
supportive treatment of breast cancer, multiple myeloma and prostate cancer justifies 
their further clinical evaluation in RCC patients. 
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Figure Legends 
 
Figure 1. The effect of bisphosphonates on cell survival. 769-P, Caki-2 and D69581 
cells were seeded at a density of 1x104 in 96-well plates and allowed to adhere 
overnight.  Media was then replaced with 100 µl/well media containing ZOL,   PAM.  
or clodronate. At time points 48 and 72 h after drug addition an MTS assay was 
performed.  The error bars represent 2 standard errors (SE). All experiments were 
repeated at least 4 times. 
 
Figure 2. Cell survival after exposure to different concentrations of bisphosphonates 
for up to 72 hours. Cells were seeded at a density of 1x104 in 96-well plates and 
allowed to adhere overnight.  Media was then replaced with 100 µl/well media 
containing 0 µM, 10 µM or 100 µM of ZOL or PAM.  An MTS assay was performed 
after 0.5, 1, 3 and 24 , 48 and 72 hours after drug exposure.  The error bars represent 
the standard deviation of triplicate wells. All experiments were repeated 4 times, and 
the error bars represent 2SE. Representative examples for the 769P and D69581 cell 
lines are shown.  
 
Figure 3. The effect of isoprenoids on loss of cell viability after exposure to 
bisphosphonates. Cells were plated at 1 x 104/ml in 24 well plates and allowed to 
adhere overnight and treated. Farnesol (FOH) or geranylgeroniol (GGOH) were added 
for 3 hours prior to exposure to bisphosphonate. After 24 hours, culture medium was 
changed and 40mM of either FOH or GGOH was added. Cells were evaluated at day 
4 for viability by MTS assay. All experiments were repeated 3 times. Representative 
examples of treatment with ZOL and FFOH/GGOH is shown. Addition of isoprenoids 
resulted in increase cell viability for both ZOL and PAM treatments and reached 
statistical significance with ZOL and FOH ( p <0.012). 
 
Figure 4. Morphological changes in cell lines after exposure to bisphosphonates. 
Changes were more marked after ZOL exposure and typical of apoptosis (cell 
shrinkage and blebbing of cell surface).  There was early loss of adherence in the  
769-P cell line. 
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Figure 5. Cell cycle analysis using the Apo Direct assay on untreated control cells and 
after 72 hour exposure to ZOL and PAM. Each experiment was repeated at least 3 
times, results are shown with standard deviations.  
 
Figure 6. Caspase 3 activation assay for Caki-2 cell line exposed to PAM and ZOL for 
72 hours. Clear evidence of caspase 3 activation is seen only after exposure to ZOL. 
 
Figure 7. Localisation of MSH-2 protein after treatment with bisphosphonates using 
immunofluorescence microscopy. The distribution of MSH-2 protein was very similar 
in control (A) and PAM-treated cells (B) with expression restricted to the nucleus. 
After ZOL exposure however, the distribution of MSH2 protein changed markedly 
and adopted a peri-nuclear and cytoplasmic distribution (C). 
 
 
 
Table Legend 
 
Table 1. Assessment of apoptotic effect of bisphosphonates at 72 hours using Apo 
Direct assay. Analysis of 3 repeated experiments is shown.  
 
Table 2. Kinetiworks analysis of apoptosis protein expression of caki-2 cell lines after 
exposure to PAM and ZOL compared to untreated cells. All numerical values are 
relative to control (untreated) cell line.  Percentage change in expression compared to 
control is shown in parentheses, a minus value indicates a reduction in expression. 
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Figure 6  
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Figure 7 
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Table 1 .  
              
 
 
  
       769P CCaki2       D6981  
    
Untreated 1.5 2.5 2.7
St dev 0.20 2.05 0.88
Error 0.12 1.18 0.51
    
    
ZOL 74.6 95.3 94.0
St dev 20.74 2.08 5
Error 11.97 1.2 2.88
    
    
PAM 51.3 4.7 83.3
St dev 22.50 3.92 8.14
Error 12.99 2.26 4.70
 
% apoptosis 
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Table 2.  
 
 
 
Protein Treatment  
 
 Control                PAM                     ZOL 
AIF 1125 622 (-44.7) 557 (-50.4) 
CAS 683 334 (-51) 61 (-91) 
CASP2 p12 193 93 (-51.8)  undetectable
CASP5 int 9481 9970 (4.9) 9235 (-2.5) 
CASP5 p20 4188 7016 (40.3) 2947 (29.6) 
Cytochrome C 1161 716 (-38.3) 658 (-43.3) 
DAXX 325 415 (27.6) 58 (-82.2) 
DFF45-L 1025 777 (-24) 305 (-70.2) 
DFF45-S 354 237 (-33) 91 (-74.3) 
FasL 1513 1189 (-21.4) 1854 (18.3) 
MSH2 1011 772 (-23.6) 181 (-82.1) 
PARP p116 162 847 (80.8) 31 (-80.8) 
PARP p89 233 69 (-70.3) 239 (2.5) 
PERP 2219 3047 (27.1) 1174 (-47.1) 
proCASP1 alpha 548 419 (-24.9) 131 (-76.1) 
proCASP1 beta 814 715 (-12.1) 407 (-50) 
proCASP12 736 743 (0.9) 624 (-15.2) 
proCASP3 1041 543 (-47.8) 233 (-77.6) 
proCASP4 383 223 (-41.8) 72 (-81.2) 
proCASP6 518 273 (-47.2) 149 (-71.2) 
proCASP7 1168 1680 (30.4) 1648 (29.1) 
proCASP8 6638 3767 (-43.2) 2521 (-62) 
proCASP9 342 312 (-8.7) 227 (-33.6) 
SOCS4 266 407 (34.6) 547 (51.3) 
SOD (Cu/Zn) 20960 23109 (9.2) 46246 (54.6) 
SODD 321 174 (-45.8) 126 (-60.7) 
XIAP 136 111 (-18)  undetectable
 
 
 
 
 
 
